Clinical Trials Logo

Cirrhosis clinical trials

View clinical trials related to Cirrhosis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06348004 Active, not recruiting - Cirrhosis Clinical Trials

The Association Between Albumin Administration and Short-term Rebleeding Risk in Cirrhosis Patients With Acute Variceal Hemorrhage and Stable Hemodynamics

Start date: February 1, 2024
Phase:
Study type: Observational

The impact of albumin administration in cirrhotics with acute variceal hemorrhage (AVH) is controversial. We aim to investigate the short-term rebleeding risk associated with albumin administration in a retrospective study of hospitalized cirrhotics with AVH with stable hemodynamics. This retrospective analysis includes clinical data of cirrhosis patients with acute variceal bleeding admitted to our hospital from January 2021 to October 2023. Propensity score matching will be performed to account for potential confounders associated with albumin use for outcome analysis. According to the outcome, patients will be divided into rebleeding group and non-rebleeding group. To investigate the impact of albumin infusion on the rebleeding risk in the propensity-matched cohort, patients will be divided into albumin user group and albumin non-user group. The primary outcome is the rebleeding risk within 30 days after discharge.

NCT ID: NCT05413083 Active, not recruiting - Cirrhosis Clinical Trials

Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis

DYNACORD-AD
Start date: June 6, 2022
Phase:
Study type: Observational [Patient Registry]

This project aims to investigate cardiac function in patients with cirrhosis in the acute setting. Acute decompensation and acute-on-chronic liver failure are major events in the life of a patient as they herald disease progression and negative prognosis. Cardiocirculatory function will be assessed by serial assessments in patients admitted for acute decompensation of cirrhosis.

NCT ID: NCT04642391 Active, not recruiting - Cirrhosis Clinical Trials

Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis

Start date: August 2, 2021
Phase:
Study type: Observational

This study aims to define the prevalence and potential pathophysiologic mechanisms underlying relative adrenal insufficiency (RAI) in outpatients with decompensated cirrhosis. Patients will be followed prospectively for up to two years to determine incidence of RAI, whether RAI represents a permanent or dynamic physiologic state in cirrhosis, and to determine whether RAI in this setting is associated with important clinical outcomes.

NCT ID: NCT04365868 Active, not recruiting - Cirrhosis Clinical Trials

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

NAVIGATE
Start date: June 22, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline.

NCT ID: NCT03705078 Active, not recruiting - Cirrhosis Clinical Trials

"Early TIPS" Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices

GAVAPROSEC
Start date: January 3, 2019
Phase: N/A
Study type: Interventional

The primary objective of the study is to demonstrate the superiority of an "early tips" strategy over standard treatment by glue obliteration (G0) in preventing bleeding recurrence or death at one year after a non GOV1 gastric variceal bleeding in cirrhotic patients initially treated by GO.

NCT ID: NCT03654053 Active, not recruiting - Cirrhosis Clinical Trials

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

SACRED
Start date: October 2, 2020
Phase: Phase 3
Study type: Interventional

This phase III, randomized, double-blind, placebo-controlled, multi-center study seeks to test whether simvastatin, a statin usually used to lower cholesterol to prevent heart problems and strokes, can lower the risk of hepatic decompensation (developing symptoms of cirrhosis) in U.S. Veterans who have compensated cirrhosis (the liver is scarred and damaged but there are no symptoms). The study will also explore how changes or differences in genes effect the safety and effectiveness of using statins and how the use of statins affects quality of life.

NCT ID: NCT03278925 Active, not recruiting - Cirrhosis Clinical Trials

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

Start date: August 9, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of defined green tea catechin extract and to see how well it works in preventing liver cancer in participants with cirrhosis. Higher levels of the molecule gamma-OHPdG may be found in participants with cirrhosis, which may mean a higher risk of the development of liver cancer. Defined green tea catechin extract may work better to lower levels of gamma-OHPdG and prevent the development of liver cancer.

NCT ID: NCT03123666 Active, not recruiting - Cirrhosis Clinical Trials

Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis

Start date: April 19, 2017
Phase: N/A
Study type: Interventional

Informed consent obtained from the patient or the patient's legal surrogate. The window for randomization and initiation of study drug infusion is 2 days from day of Admission. All further time points are relative to the day of randomization. Patients will be randomized (1:1) to receive either recombinant human GM-CSF or placebo. Using randomized block design of 10 each generated by computer and provided in sequential, sealed, opaque envelopes. Subjects will be stratified based on Child status. Patients who fulfil the inclusion criteria will receive either slow IV infusion of GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer for 7 days OR Placebo(saline infusion and saline nebulization). Standard medical care will be given in both limbs.

NCT ID: NCT03085342 Active, not recruiting - Cirrhosis Clinical Trials

Evaluation of Hepatic Fibrosis on Multiparametric MRI

Start date: April 4, 2017
Phase: N/A
Study type: Interventional

As cirrhosis progresses, alteration of hemodynamics develops and decreased portal flow is often observed. Since direct measurement of portal pressure (HVPG) is invasive, non-invasive methods have drawn a lot of attention. MRI is one of the non-invasive methods and it is able to provide multiparametric data in one examination. Herein, we evaluate hepatic fibrosis with different stage using multiparametric MRI with emphasis on portal flow measurement.

NCT ID: NCT03069339 Active, not recruiting - Cirrhosis Clinical Trials

Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis

Start date: March 15, 2017
Phase: N/A
Study type: Interventional

Study Design: Open labeled randomized controlled trial. The study will be conducted on patients attending outpatient or admitted to admitted to Department of Hepatology from January 2017 to December 2018 at ILBS, New Delhi